Idera Pharmaceuticals Inc (NASDAQ:IDRA) Receives $14.33 Average PT from Brokerages

Share on StockTwits

Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) have received a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $14.33.

IDRA has been the topic of several research reports. ValuEngine upgraded shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Wedbush reiterated an “outperform” rating on shares of Idera Pharmaceuticals in a report on Friday, May 3rd. Finally, Zacks Investment Research lowered shares of Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday.

Several institutional investors and hedge funds have recently bought and sold shares of IDRA. Natixis raised its holdings in shares of Idera Pharmaceuticals by 61.7% in the 2nd quarter. Natixis now owns 743,618 shares of the biotechnology company’s stock worth $1,985,000 after acquiring an additional 283,802 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Idera Pharmaceuticals by 36.1% in the 4th quarter. Millennium Management LLC now owns 602,639 shares of the biotechnology company’s stock worth $1,669,000 after acquiring an additional 159,916 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Idera Pharmaceuticals by 273.5% in the 2nd quarter. Acadian Asset Management LLC now owns 165,044 shares of the biotechnology company’s stock worth $440,000 after acquiring an additional 120,861 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Idera Pharmaceuticals in the 2nd quarter worth about $237,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Idera Pharmaceuticals in the 2nd quarter worth about $228,000. Institutional investors own 42.91% of the company’s stock.

Shares of NASDAQ IDRA opened at $2.26 on Monday. The firm’s 50-day moving average is $2.55. Idera Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $10.95. The firm has a market capitalization of $65.47 million, a price-to-earnings ratio of -0.99 and a beta of 2.45.

Idera Pharmaceuticals (NASDAQ:IDRA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.03. Idera Pharmaceuticals had a negative net margin of 9,045.47% and a negative return on equity of 71.91%. The firm had revenue of $1.45 million for the quarter, compared to analyst estimates of $0.10 million. On average, equities research analysts anticipate that Idera Pharmaceuticals will post -1.64 earnings per share for the current year.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

Featured Story: The limitations of an equal weight rating

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
Line Corp  Shares Sold by CSat Investment Advisory L.P.
Line Corp Shares Sold by CSat Investment Advisory L.P.


© 2006-2019 Ticker Report